Primary immunodeficiencies (PID) are a group of genetic disorders that disrupt the normal functioning of the immune system, making individuals susceptible to chronic and recurrent infections, autoimmunity, and malignancies. While traditional treatments such as antibiotics and immunoglobulin replacement therapy can help manage symptoms, hematopoietic stem cell transplantation (HSCT) has emerged as a potentially curative option for many PID.

HSCT involves replacing the patient's defective immune system with a healthy immune system from a donor. The stem cells used for HSCT are typically obtained https://stemplus.clinic/disease-treatment/primary-immunodeficiency/ from bone marrow, peripheral blood, or umbilical cord blood. These stem cells have the ability to differentiate into various types of blood cells, including immune cells. After HSCT, the transplanted stem cells migrate to the patient's bone marrow, where they begin to produce new, healthy immune cells.

HSCT has achieved significant success in the treatment of a wide range of PID, including severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome, and chronic granulomatous disease. The success of HSCT depends on several factors, including the type of PID, the patient's age, the availability of a suitable donor, and the patient's overall health.